Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines (Q84933381)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

R Grepin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

M Guyot

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

M Jacquin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

E Chamorey

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

A Sudaka

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

C Serdjebi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

B Lacarelle

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

J-Y Scoazec

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

S Negrier

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

H Simonnet

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

G Pages

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

12 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1683-1694

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2011.360

12 February 2020

exact match

0 references

cites work

Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

CXC chemokines located in the 4q21 region are up-regulated in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Platelet-associated PF-4 as a biomarker of early tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

VEGF-A splicing: the key to anti-angiogenic therapeutics?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Microenvironmental regulation of metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Platelet factor-4 is an indicator of blood count recovery in acute myeloid leukemia patients in complete remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

ELR+-CXC chemokines and their receptors in early metanephric development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Endothelial cell plasticity: how to become and remain a lymphatic endothelial cell

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Monocyte-derived CXCL7 peptides in the marrow microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

The role of CXC chemokines and their receptors in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Interleukin-8 and human cancer biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.360

31 March 2020

Identifiers

DOI

10.1038/ONC.2011.360

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909141%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

12 February 2020

0 references

1 reference